Enterprise Value
110.2M
Cash
223.8M
Avg Qtr Burn
-16.23M
Short % of Float
17.27%
Insider Ownership
3.14%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CABA-201 (4-1BB CD19-CAR T) Details Systemic sclerosis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Myasthenia gravis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Systemic lupus erythematosus, Lupus nephritis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Idiopathic inflammatory myopathy / myositis, Anti-synthetase syndrome, Immune-mediated necrotizing myopathy, Dermatomyositis | Phase 1/2 Data readout | |
MuSK-CAART Details Autoimmune disease, Myasthenia gravis | Phase 1 Data readout | |
DSG3-CAART Details Mucosal Pemphigus Vulgaris | Phase 1 Data readout |